Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.

Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2013 Apr;41(4):387-97.e1. doi: 10.1016/j.exphem.2012.11.005. Epub 2012 Nov 23.

PMID:
23178378
2.

Diabetes impairs hematopoietic stem cell mobilization by altering niche function.

Ferraro F, Lymperi S, Méndez-Ferrer S, Saez B, Spencer JA, Yeap BY, Masselli E, Graiani G, Prezioso L, Rizzini EL, Mangoni M, Rizzoli V, Sykes SM, Lin CP, Frenette PS, Quaini F, Scadden DT.

Sci Transl Med. 2011 Oct 12;3(104):104ra101. doi: 10.1126/scitranslmed.3002191.

3.

Synthetic polyamines as potential amine oxidase inhibitors: a preliminary study.

Emanuela B, Minarini A, Tumiatti V, Milelli A, Lunelli M, Pegoraro M, Rizzoli V, Di Paolo ML.

Amino Acids. 2012 Feb;42(2-3):913-28. doi: 10.1007/s00726-011-1006-z. Epub 2011 Aug 20.

PMID:
21858471
4.

Interactions of melatonin with mammalian mitochondria. Reducer of energy capacity and amplifier of permeability transition.

Martinis P, Zago L, Maritati M, Battaglia V, Grancara S, Rizzoli V, Agostinelli E, Bragadin M, Toninello A.

Amino Acids. 2012 May;42(5):1827-37. doi: 10.1007/s00726-011-0903-5. Epub 2011 Apr 8.

PMID:
21476076
5.

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N.

Leukemia. 2011 Mar;25(3):527-37. doi: 10.1038/leu.2010.270. Epub 2010 Nov 23.

6.

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2011 Jan;39(1):55-65. doi: 10.1016/j.exphem.2010.10.005. Epub 2010 Oct 25.

PMID:
20977926
7.

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N.

Leukemia. 2010 Nov;24(11):1967-70. doi: 10.1038/leu.2010.193. Epub 2010 Sep 2. No abstract available.

PMID:
20811474
8.

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients.

Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V.

Leukemia. 2010 Jul;24(7):1368-70. doi: 10.1038/leu.2010.96. Epub 2010 May 20. No abstract available.

PMID:
20485369
9.

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).

Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, Rizzoli V, Borlenghi E, Gaidano G, Magro D, Torelli G, Muus P, Venditti A, Cacciola E, Lauria F, Vignetti M, de Witte T.

Br J Haematol. 2010 May;149(3):376-82. doi: 10.1111/j.1365-2141.2010.08095.x. Epub 2010 Mar 8.

10.

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N.

Exp Hematol. 2010 Feb;38(2):141-53. doi: 10.1016/j.exphem.2009.11.009. Epub 2009 Dec 4.

PMID:
19963035
11.

The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting.

Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M, Bonati A.

Clin Cancer Res. 2009 Nov 1;15(21):6495-502. doi: 10.1158/1078-0432.CCR-09-1229. Epub 2009 Oct 27.

12.

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

Giuliani N, Mangoni M, Rizzoli V.

Exp Hematol. 2009 Aug;37(8):879-86. doi: 10.1016/j.exphem.2009.04.004. Epub 2009 May 14. Review.

PMID:
19446662
13.

Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix protein.

Lisignoli G, Codeluppi K, Todoerti K, Manferdini C, Piacentini A, Zini N, Grassi F, Cattini L, Piva R, Rizzoli V, Facchini A, Giuliani N, Neri A.

J Cell Physiol. 2009 Aug;220(2):401-9. doi: 10.1002/jcp.21779.

PMID:
19365806
14.

Impact of XIAP protein levels on the survival of myeloma cells.

Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S.

Haematologica. 2009 Jan;94(1):87-93. doi: 10.3324/haematol.13483. Epub 2008 Nov 10.

15.

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V.

Cancer Res. 2008 Aug 15;68(16):6840-50. doi: 10.1158/0008-5472.CAN-08-0402.

16.

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A.

Blood. 2008 Sep 15;112(6):2450-62. doi: 10.1182/blood-2007-10-114348. Epub 2008 Jun 26.

PMID:
18583568
17.

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, Taverniti G, Di Carlo E, Cutrona G, Perfetti V, Rizzoli V, Ribatti D, Pistoia V.

Blood. 2008 Aug 1;112(3):750-9. doi: 10.1182/blood-2008-02-139378. Epub 2008 May 12.

18.
19.

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis.

Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V, Giuliani N.

Blood. 2007 Dec 15;110(13):4464-75. Epub 2007 Sep 11. Erratum in: Blood. 2008 Sep 1;112(5):2170..

PMID:
17848618
20.

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, Sala R, Mangoni M, Rizzoli V.

Cancer Res. 2007 Aug 15;67(16):7665-74.

21.

Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.

Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM.

Leuk Res. 2008 Jan;32(1):49-53. Epub 2007 May 23.

PMID:
17512053
22.

MDR1 polymorphism influences the outcome of multiple myeloma patients.

Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Rossi AM, Petrini M.

Br J Haematol. 2007 Jun;137(5):454-6.

PMID:
17488488
23.

A translocation t(4; 13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma.

Sammarelli G, Zannoni M, Bonomini S, Delsignore R, Rizzoli V, Sianesi M, Caramatti C.

Tumori. 2007 Jan-Feb;93(1):97-9.

PMID:
17455879
24.

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V.

Blood. 2007 Jul 1;110(1):334-8. Epub 2007 Mar 19.

PMID:
17371942
25.

Targeting pathways mediating bone disease.

Giuliani N, Morandi F, Tagliaferri S, Rizzoli V.

Curr Pharm Biotechnol. 2006 Dec;7(6):423-9. Review.

PMID:
17168658
26.

Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.

Bonati A, Rizzoli V, Lunghi P.

Curr Pharm Biotechnol. 2006 Dec;7(6):397-405. Review.

PMID:
17168655
27.

CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.

Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V.

Haematologica. 2006 Nov;91(11):1489-97.

28.

Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation.

Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM.

Leukemia. 2007 Jan;21(1):176-8. Epub 2006 Oct 26. No abstract available.

PMID:
17066090
29.

Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.

Jehn U, Suciu S, Thomas X, Lefrère F, Muus P, Berneman Z, Marie JP, Adamo F, Fillet G, Nobile F, Ricciuti F, Leone G, Rizzoli V, Montanaro M, Beeldens F, Fazi P, Mandelli F, Willemze R, de Witte T, Amadori S.

Leukemia. 2006 Oct;20(10):1723-30. Epub 2006 Aug 17.

30.

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Giuliani N, Rizzoli V, Roodman GD.

Blood. 2006 Dec 15;108(13):3992-6. Epub 2006 Aug 17. Review.

PMID:
16917004
31.

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.

Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G, Rizzoli V.

Blood. 2006 Jan 15;107(2):841-2. No abstract available.

PMID:
16401825
32.

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients.

Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, Mancini C, Pedrazzoni M, Crugnola M, Rizzoli V, Giuliani N.

Leukemia. 2005 Dec;19(12):2166-76.

PMID:
16208410
33.

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.

Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V.

Blood. 2005 Oct 1;106(7):2472-83. Epub 2005 Jun 2.

PMID:
15933061
34.

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N.

Blood. 2005 Aug 15;106(4):1407-14. Epub 2005 May 5.

PMID:
15878977
35.

Update on the pathogenesis of osteolysis in multiple myeloma patients.

Giuliani N, Colla S, Rizzoli V.

Acta Biomed. 2004 Dec;75(3):143-52. Review.

PMID:
15796087
36.

Angiogenic switch in multiple myeloma.

Giuliani N, Colla S, Rizzoli V.

Hematology. 2004 Oct-Dec;9(5-6):377-81. Review.

PMID:
15763977
37.

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells.

Giuliani N, Colla S, Morandi F, Barille-Nion S, Rizzoli V.

Haematologica. 2005 Feb;90(2):275-8.

38.

Angiopoietin-1 and myeloma-induced angiogenesis.

Giuliani N, Colla S, Morandi F, Rizzoli V.

Leuk Lymphoma. 2005 Jan;46(1):29-33. Review.

PMID:
15621778
39.
40.

Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.

Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V, Zupo S, Marino G, Rubagotti A, Polacco A, Spriano M, Vimercati R, Congiu AM, Ravetti JL, Aversa S, Candela M, Patti C.

Leuk Lymphoma. 2004 Jun;45(6):1141-7.

PMID:
15359993
41.
42.

Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.

Colla S, Sammarelli G, Crugnola M, Ascani S, Sabbatini E, Bonomini S, Hojden M, Craviotto L, De Celis I, Morandi F, Caramatti C, Rizzoli V, Giuliani N.

Eur J Haematol. 2004 May;72(5):361-5. Review.

PMID:
15059073
43.

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R.

Cancer Res. 2004 Jan 15;64(2):772-3; author reply 774-5. No abstract available.

44.

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A.

Leukemia. 2004 Mar;18(3):628-35.

PMID:
14737074
45.

Do human myeloma cells directly produce basic FGF?

Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, Hojden M, Martella E, Chisesi T, Rizzoli V, Giuliani N.

Blood. 2003 Oct 15;102(8):3071-2; author reply 3072-3. No abstract available.

PMID:
14527891
46.

Angiopoietins expression by human myeloma cells.

Colla S, Roti G, Rizzoli V, Giuliani N.

Haematologica. 2003 Jun;88(6):ELT20; author reply ELT21. No abstract available.

47.

Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes.

Giuliani N, Caramatti C, Roti G, Geata A, Colla S, Bonomini S, Hojden M, La Monica S, Sammarelli G, Lazzaretti M, Craviotto L, Mangoni L, Rizzoli V.

J Clin Oncol. 2003 May 1;21(9):1887-8. No abstract available.

PMID:
12721268
48.

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.

Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V.

Blood. 2003 Jul 15;102(2):638-45. Epub 2003 Mar 20.

PMID:
12649156
49.

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V.

Blood. 2002 Dec 15;100(13):4615-21. Epub 2002 Aug 8.

PMID:
12393684
50.

The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.

Olavarria E, Reiffers J, Boque C, Sureda A, Meloni G, Michallet M, Clark RE, Blaise D, Carella AM, Cahn JY, Jouet JP, Rizzoli V, Van Biezen A, Gratwohl A, Goldman JM, Niederwieser D, Apperley JF.

Br J Haematol. 2002 Sep;118(3):762-70.

PMID:
12181043

Supplemental Content

Loading ...
Support Center